Existing backers Takeda, Deerfield and Bay City Capital have provided $10m to help progress research from multiple institutions.

Bridge Medicines, a US-based drug discovery company exploiting research from Memorial Sloan Kettering Cancer Center, Rockefeller University and Weill Cornell Medicine, has secured $10m from existing shareholders. Pharmaceutical firm Takeda and investment firms Deerfield Management and Bay City Capital provided the capital. Launched in 2016, Bridge Medicines aims to catalyse clinical drug candidates based on…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.